Guolian Minsheng Securities·2026-02-01 05:23Investment Rating - The report maintains a "Hold" rating for the pharmaceutical industry [3] Core Insights - The report highlights the focus on innovation and internationalization within the pharmaceutical industry, with an emphasis on the development of innovative drugs and the exploration of new technological avenues [9][41] - The report suggests a dual investment strategy: one focusing on the rotation of technological innovation from 0 to 1 and the other on value recovery, emphasizing stocks with reasonable valuations and performance growth catalysts [9] - Key investment opportunities are identified in the CRO sector, with specific companies recommended for attention, including Tigermed, Baioo, and WuXi AppTec [9] Summary by Sections 1. Insights from JP Morgan Conference - The report discusses several new therapeutic targets presented at the JP Morgan conference, including Lp(a) siRNA therapy, FXI monoclonal antibodies, and TL1A monoclonal antibodies, all expected to yield phase III data in 2026 [12][18][22][34] - Notably, the Lp(a) siRNA drug Pelacarsen aims to reduce cardiovascular risks associated with Lp(a) levels through a novel mechanism [12][15] - FXI monoclonal antibodies are being developed for stroke prevention in atrial fibrillation patients, with promising data expected in 2026 [18][20] - TL1A monoclonal antibodies are being explored for ulcerative colitis, with data readouts anticipated in 2026 [22] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical index experienced a week-over-week decline of 3.31%, underperforming both the ChiNext and CSI 300 indices [41] - The total trading volume for pharmaceuticals was 685.97 billion yuan, accounting for 4.52% of the total market, which is below the historical average of 7.10% [62] - The report notes that the pharmaceutical sector's valuation is currently below the historical average, with a PE ratio of 29.40, indicating a relative undervaluation [58] 3. Individual Stock Performance - The report lists the top-performing stocks for the week, including Cap Bio and Hualan Biological, while highlighting underperformers such as *ST Sailong and Hexin Instruments [66] - Monthly performance rankings show significant gains for stocks like Hongbo Pharmaceutical and Baolait, while others like Hezhong China faced substantial declines [66]